Lee and colleagues have shown that CDK4 plays a central role in glucose homeostasis. Insulin activates cyclin D1-CDK4, leading to a decrease in circulating glucose as a consequence of the down-regulation of main genes involved in liver gluconeogenesis.
CommentaryIn recent years, our knowledge of CDK regulation has improved significantly and is no longer restricted to just its role in the control of cell cycle progression. Cyclin-dependent kinases (CDKs) are serine/ threonine protein kinases that are associated with their specific partners, cyclins which phosphorylate their protein targets. Thus, the cyclin-CDK complex works as a holoenzyme. The control of cell cycle progression by cyclin-CDK complexes was first studied several years ago, in the context of high proliferation rates and cancer. Understanding how CDKs function was one of the main aims of these studies, as the loss of this regulation can alter cell proliferation rates which, in the worst case scenario, may translate into malignant tumours.The cell cycle is mainly divided into G1, S, G2, and M phases, and transition between these phases is strongly controlled. Transition from G1 to S is tightly regulated and depends on the activity of the G1 phase cyclin-CDK complexes, where CDK can be CDK4 or CDK6 and is associated with G1 D-type cyclins (D1, D2 and D3). In addition, there is an upper-level control of the activity of cyclin-CDK complexes determined by the presence or absence of two families of CDK inhibitors (CKIs), INK4 proteins and the Cip/Kip family, respectively. When the G1 phase cyclin-CDK complexes are active, they regulate the transition to the S phase by a direct phosphorylation of the retinoblastoma protein (Rb). Rb hyperphosphorylation mediates the release of the E2F transcription factor, allowing its transit to the nucleus, where it can promote the transcription of several genes involved in cell cycle progression, apoptosis, and DNA synthesis [1].Besides their well-described role in the control of cell cycle progression, in recent years a new role for CDKs has emerged beyond the context of cell cycle progression, as a master regulator of metabolism. In this sense, the CDK4-RB-E2F axis and other cell cycle components have acquired a main role in the control of insulin secretion by pancreatic β-cells [2,3], of oxidative metabolism [4] and of adipogenesis [5][6][7][8].Much more recently, a unique study designed by the Puigserver group [9] demonstrated that CDK4 plays a central role in glucose homeostasis, specifically in liver gluconeogenesis. Briefly, insulin activates AKT (also known as PKB) through a cascade of correlative phosphorylation with the insulin receptor, insulin receptor substrates, PI3K and finally PDK1 (Figure 1). Once AKT is activated, AKT phosphorylates several substrates, among them, Glycogen synthase kinase 3 (GSK3), at Ser 21 in α subunit and at Ser 9 in β subunit, resulting in the inhibition of GSK3 kinase activity [10][11][12][13]. GSK3 is a well-conserved kinase, originally identified as an enzyme that regulat...